Most Read Articles
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
22 May 2017
Consumption of glutinous brown rice (GBR) controls the whole-day glucose profile of patients with type 2 diabetes mellitus (T2DM), mainly by lowering postprandial glucose excursion, reports a study. In addition, GBR is preferred over nonglutinous brown rice (BR) in terms of palatability.
10 Oct 2016
Use of dipeptidyl peptidase-4 (DPP-4) inhibitors may reduce the risk of mortality and the combination of myocardial infarction and ischaemic stroke in type 2 diabetes (T2D), without increasing the risk of hospitalisation for heart failure even in T2D patients with pre-existing HF, a nationwide cohort study from Taiwan suggests.

Novel Approaches in the Treatment of Dyslipidaemia and T2DM

16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
22 May 2017
Consumption of glutinous brown rice (GBR) controls the whole-day glucose profile of patients with type 2 diabetes mellitus (T2DM), mainly by lowering postprandial glucose excursion, reports a study. In addition, GBR is preferred over nonglutinous brown rice (BR) in terms of palatability.
10 Oct 2016
Use of dipeptidyl peptidase-4 (DPP-4) inhibitors may reduce the risk of mortality and the combination of myocardial infarction and ischaemic stroke in type 2 diabetes (T2D), without increasing the risk of hospitalisation for heart failure even in T2D patients with pre-existing HF, a nationwide cohort study from Taiwan suggests.